Psilocybin: From Psychiatric Pariah to Perceived Panacea
Adrienne Grzenda, Gregory A. Fonzo, Aaron Wolfgang, Bryan R. Barksdale, John H. Krystal, Linda L. Carpenter, Nina V. Kraguljac, William M. Mcdonald, Alik S. Widge, Carolyn I. Rodríguez, Charles B. Nemeroff
American Journal of Psychiatry 2025 DOI: 10.1176/appi.ajp.20230682 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psilocybin |
| Keywords | Panacea medicine Pariah group Psychotherapist Hallucinogen |
| Citations | 14 |
| Key findings | The evidence is currently insufficient to recommend psilocybin with PST as a psychiatric treatment. |
Abstract
The evidence is currently insufficient to recommend psilocybin with PST as a psychiatric treatment. Additional rigorously designed clinical trials are needed to definitively establish efficacy in larger and more diverse samples, address dosing considerations, improve blinding, and provide information on mechanisms of action and moderators of clinical response. Head-to-head comparisons with other evidence-based treatments will better inform the potential future role of psilocybin with PST in the treatment of major psychiatric disorders.